Dupixent

Active Ingredient(s): Dupilumab
FDA Approved: * March 28, 2017
Pharm Company: * REGENERON PHARMACEUTICALS
Category: Skin Care

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Dupixent Overview

Dupilumab, sold under the trade name Dupixent, is a monoclonal antibody designed for the treatment of allergic diseases such as eczema (atopic dermatitis).[1][2] Side effects include allergic reactions, cold sores, and inflammation of the cornea.[2] It was developed by Regeneron Pharmaceuticals and Sanofi Genzyme.[3][4] It received FDA approval for moderate-to-severe atopic dermatitis in 2017.[2] A...

Read more Dupixent Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dupilumab

Recent Dupixent Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dupilumab
  • Injection: 150mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Dupixent: (2 results)

Sorted by National Drug Code
  • 0024-5914 Dupixent 300 mg/2ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC
  • 0024-5916 Dupixent 300 mg/2ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC

Other drugs which contain Dupilumab or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 13 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA